Lennox-Gastaut syndrome. Management update

Area of Science:

• Pediatric Neurology
• Epileptology
• Clinical Neuroscience

Background:

• Lennox-Gastaut syndrome (LGS) is a severe pediatric epilepsy characterized by mixed seizures, cognitive decline, and specific EEG patterns.
• Atonic seizures in LGS lead to dangerous drop attacks, increasing injury risk and reducing quality of life.
• Seizures in LGS are often refractory to multiple antiepileptic drugs (AEDs).

Purpose of the Study:

• To provide an updated overview of Lennox-Gastaut syndrome.
• To review current and emerging treatment options for LGS.
• To highlight the need for comparative trials of LGS interventions.

Main Methods:

• Literature review of Lennox-Gastaut syndrome and its management.
• Analysis of available pharmacological treatments, including newer AEDs.
• Discussion of non-pharmacological interventions and their role.

Main Results:

• Newer antiepileptic drugs (AEDs), such as rufinamide, are available for LGS treatment.
• Non-pharmacological options like ketogenic diet, vagus nerve stimulation, and epilepsy surgery are crucial when AEDs fail.
• While complete seizure control remains difficult, new therapies offer improved prospects.

Conclusions:

• Lennox-Gastaut syndrome management requires a multimodal approach.
• The addition of novel therapies provides cautious optimism for patients and families.
• Long-term randomized controlled trials are essential to evaluate the efficacy and tolerability of different LGS treatments.